Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp (PROF) delivers innovative MRI-guided therapeutic solutions for prostate ablation, merging precision imaging with minimally invasive treatment. This news hub provides investors and healthcare professionals with timely updates on clinical advancements, regulatory milestones, and corporate developments shaping the future of image-guided therapies.
Access verified information on PROF's TULSA-PRO system adoption, partnership announcements, and financial performance. Our curated news collection features earnings reports, research publications, and market analysis to help stakeholders track the company's progress in advancing non-invasive treatment options.
Key coverage areas include FDA clearances, clinical trial outcomes, technology enhancements, and strategic collaborations. Stay informed about developments in therapeutic ultrasound applications and the growing adoption of closed-loop thermal control systems in urology practices worldwide.
Bookmark this page for direct access to primary source materials and expert commentary on PROF's role in transforming prostate cancer treatment paradigms through cutting-edge medical device innovation.
Profound Medical (NASDAQ: PROF; TSX: PRN), a commercial-stage medical device company focused on developing incision-free ablation therapies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments from the period. Investors can access the live call through registration and the broadcast will be archived on the company's website under the Investors section.
Profound Medical Corp (NASDAQ:PROF) has announced details for its hybrid investor event scheduled for April 28, 2025, during the AUA Annual Meeting at the Waldorf Astoria in Las Vegas. The 90-minute event, running from 3:30-5:00 PM PT, will feature key presentations from company leadership and medical experts.
The agenda includes:
- Dr. Mathieu Burtnyk presenting CAPTAIN study results comparing TULSA to radical prostatectomy
- Dr. Ram Pathak sharing TULSA-PRO® clinical outcomes
- CEO Dr. Arun Menawat discussing TULSA-AI® for BPH and TULSA+ program with Siemens Healthineers
- Dr. Naveen Kella presenting on TULSA's BPH treatment capabilities
- CCO Tom Tamberrino outlining TULSA+ commercial strategy
The event will conclude with a Q&A session and will be available via webcast on the company's website.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN) has announced a hybrid investor event scheduled for April 28, 2025, during the American Urological Association (AUA) Annual Meeting in Las Vegas. The event will run from 3:30-5:00 PM PT (6:30-8:00 PM ET).
The program will feature presentations from both management and leading physicians, focusing on four key areas:
- TULSA-PRO® technology and its versatility in treating prostate disease patients
- Peri-operative results from the Level 1 CAPTAIN post-market study comparing TULSA procedure to radical prostatectomy
- Introduction of the new TULSA-AI® module for BPH, including a live technology demonstration
- Updates on the TULSA+ program, which integrates TULSA-PRO® with Siemens Healthineers' Magnetom Free.Max interventional MRI
Profound Medical Corp (NASDAQ:PROF) is under investigation by Cohen Milstein Sellers & Toll LLP following significant accounting irregularities. The company, which develops ablation therapies for diseased tissue, disclosed on March 6, 2025, that its Audit Committee discovered a revenue overstatement of $472,000 in Q1 2024.
As a result, Profound's financial statements for the first three quarters of 2024 will require restatement and reissuance. The market reacted negatively to this news, with PROF shares declining 5.9% to close at $6.86 per share on March 7, 2025.
Profound Medical (NASDAQ:PROF) reported strong Q4 2024 financial results with revenue reaching $4.2 million, marking a 108% increase compared to Q4 2023. The quarter saw $2.7 million from recurring revenue and $1.5 million from capital equipment sales.
Key Q4 highlights include executive changes with Mathieu Burtnyk promoted to President and Tom Tamberrino appointed as Chief Commercial Officer. The company entered a collaboration with Siemens Healthineers and launched the TULSA-AI® 'UA Alignment Assistant' module.
For full year 2024, revenue totaled $10.7 million, up from $7.2 million in 2023. The company reported a net loss of $27.8 million ($1.12 per share) compared to $28.3 million ($1.34 per share) in 2023. Operating expenses increased to $40.1 million from $33.0 million. As of December 31, 2024, Profound had cash of $54.9 million.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free ablation therapies for diseased tissue, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. The call will be accessible through online registration and will also be broadcast live and archived on the company's website under the Investors section.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free ablation therapies, announced a schedule change for its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation has been moved to 9:00 a.m. Pacific Time on Thursday, January 16, 2025. Interested parties can access the live broadcast and archived recording through the 'Webcasts' section of the company's website at www.profoundmedical.com.
Profound Medical (NASDAQ:PROF) announced preliminary unaudited revenues for Q4 and full year 2024. The company expects Q4 2024 revenue between $4.1-4.2 million, representing 105-110% year-over-year growth and 45-48% sequential growth. Full year 2024 revenue is anticipated at $11.1-11.2 million, compared to $7.2 million in 2023.
Starting January 1, 2025, Profound will transition to reporting financial results under U.S. GAAP and file domestic forms with the SEC, while maintaining SEDAR+ filings in Canada. The company recently completed an underwritten public offering of common shares and achieved unique reimbursement for its TULSA procedure at Urology APC Level 7 across multiple treatment settings.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free ablation therapies for diseased tissue, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a business update presentation on Thursday, January 16, 2025, at 11:15 a.m. Pacific Time in San Francisco, CA.
The presentation will be accessible to interested parties through a live broadcast and will subsequently be archived on the company's website at www.profoundmedical.com in the Investors section under 'Webcasts'.
Profound Medical Corp (NASDAQ: PROF) has successfully closed its underwritten public offering of common shares, raising US$40.25 million in gross proceeds. The offering, priced at US$7.50 per share, included the full exercise of the over-allotment option, resulting in the issuance of 5,366,705 common shares.
The net proceeds will be allocated to fund the commercialization of TULSA-PRO® system in the United States, support global development and commercialization of both TULSA-PRO® and Sonalleve® systems, and provide working capital for general corporate purposes. Raymond James and Lake Street Capital Markets served as co-lead underwriters and joint bookrunners for the offering.
